CRSP- CRSP - CRISPR Therapeutics Revenues and Earnings Beat Expectations
***Earnings per share (EPS) also surpassed analyst estimates by 59%. Looking ahead, revenue is forecast to grow 58% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.10 hours ago
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.